n increase of 36.6% over the ending backlog reported for Fiscal Year 2007.
Backlog at the beginning of the fourth quarter was $1.907 billion. Adding
the June quarter's record gross new business wins of $545.0 million to that
amount, and then subtracting $272.2 million in current quarter service
revenue and $120.7 million in cancellations, resulted in a backlog of
$2.059 billion as of June 30, 2008. The foreign exchange impact on backlog
was insignificant in the quarter. The net book-to-burn ratio was 1.56 for
the quarter, and was 1.57 for Fiscal Year 2008.
Mr. Josef H. von Rickenbach, PAREXEL's Chairman and Chief Executive
Officer stated, "The fourth quarter's financial results capped a strong
fiscal year for PAREXEL. We posted record service revenue in the fourth
quarter, and achieved full year service revenue growth of 30.0%, or
approximately 19% on a same-store constant currency adjusted basis. All
business segments contributed to the positive full-year results. We also
delivered on our commitment to improve profitability, increasing operating
margin to 9.9% in the quarter, and by 120 basis points to 9% for the full
fiscal year, while concurrently making strategic investments to help meet
our longer term goals. Notable improvements in the Perceptive Informatics
and Medical Communications businesses, as well as significant leveraging of
SG&A as a result of very strong service revenue growth in CRS, were the
primary contributors to solid operating margin expansion during the Fiscal
Year."
Mr. von Rickenbach continued, "We have clearly benefited from the
successful execution of our strategy to become a leading global provider of
complex clinical development services and technologies. Demand has been
driven by both large and small clients, an improving industry pipeline in
late stage development, and an increase in outsourcing penetration rates.
We move into the new fiscal year with good momentum, a strong and
diversified backlog, and a healthy business
'/>"/>
SOURCE PAREXEL International Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Related biology technology :1.
PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer2.
PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call3.
PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day4.
PAREXEL Expands Global Clinical Logistics Capabilities5.
Parexel Invites Public to Listen to Live Webcast of Its Investor Day June 25, 20086.
PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies7.
PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting8.
PAREXEL Reaches Agreement To Acquire ClinPhone9.
PAREXEL International to Present at Goldman Sachs 29th Annual Global Healthcare Conference10.
PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention11.
PAREXEL Appoints Leading Biostatistician Dr. Imogene Grimes to Vice President of Data Sciences Strategic Services